Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Invest Dermatol ; 135(12): 2971-2981, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26288355

ABSTRACT

DNA alkylating agents like nitrogen mustard (NM) are easily absorbed through the skin and exposure to such agents manifest not only in direct cellular death but also in triggering inflammation. We show that toxicity resulting from topical mustard exposure is mediated in part by initiating exaggerated host innate immune responses. Using an experimental model of skin exposure to NM we observe activation of inflammatory dermal macrophages that exacerbate local tissue damage in an inducible nitric oxide synthase (iNOS)-dependent manner. Subsequently these activated dermal macrophages reappear in the bone marrow to aid in disruption of hematopoiesis and contribute ultimately to mortality in an experimental mouse model of topical NM exposure. Intervention with a single dose of 25-hydroxyvitamin D3 (25(OH)D) is capable of suppressing macrophage-mediated iNOS production resulting in mitigation of local skin destruction, enhanced tissue repair, protection from marrow depletion, and rescue from severe precipitous wasting. These protective effects are recapitulated experimentally using pharmacological inhibitors of iNOS or by compounds that locally deplete skin macrophages. Taken together, these data highlight a critical unappreciated role of the host innate immune system in exacerbating injury following exposure to NM and support the translation of 25(OH)D in the therapeutic use against these chemical agents.


Subject(s)
Calcifediol/pharmacology , Immunity, Innate/drug effects , Mechlorethamine/toxicity , Animals , Bone Marrow/drug effects , Bone Marrow/pathology , Female , Lymphopenia/drug therapy , Macrophages/physiology , Mice , Mice, Inbred C57BL , Nitric Oxide Synthase Type II/antagonists & inhibitors
2.
J Invest Dermatol ; 135(2): 389-399, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25184961

ABSTRACT

Injury initiates recruitment of macrophages to support tissue repair; however, excessive macrophage activity may exacerbate tissue damage causing further destruction and subsequent delay in wound repair. Here we show that the peroxisome proliferation-activated receptor-γ agonist, rosiglitazone (Rosi), a medication recently reintroduced as a drug to treat diabetes and with known anti-inflammatory properties, paradoxically generates pro-inflammatory macrophages. This is observed in both IL-6-deficient mice and control wild-type mice experimentally induced to produce high titers of auto-antibodies against IL-6, mimicking IL-6 deficiency in human diseases. IL-6 deficiency when combined with Rosi-mediated upregulation of suppressor of cytokine signaling 3 leads to an altered ratio of nuclear signal transducer and activator of transcription 3/NF-κB that allows hyper-induction of inducible nitric oxide synthase (iNOS). Macrophages activated in this manner cause de novo tissue destruction, recapitulating human chronic wounds, and can be reversed in vivo by recombinant IL-6, blocking macrophage infiltration, or neutralizing iNOS. This study provides insight into an unanticipated paradoxical role of Rosi in mediating hyper-inflammatory macrophage activation significant for diseases associated with IL-6 deficiency.


Subject(s)
Inflammation/etiology , Interleukin-6/deficiency , Macrophage Activation/drug effects , Skin/pathology , Thiazolidinediones/pharmacology , Animals , Female , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , NF-kappa B/physiology , Nitric Oxide Synthase Type II/physiology , Rosiglitazone , STAT3 Transcription Factor/physiology , Wound Healing
SELECTION OF CITATIONS
SEARCH DETAIL
...